160 related articles for article (PubMed ID: 30966757)
1. Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; van Amerongen D
Am J Alzheimers Dis Other Demen; 2019; 34(7-8):492-499. PubMed ID: 30966757
[TBL] [Abstract][Full Text] [Related]
2. Impact of coexisting overactive bladder in Medicare patients with osteoporosis.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; Kirby C; Abbott P
Arch Gerontol Geriatr; 2018; 75():44-50. PubMed ID: 29180131
[TBL] [Abstract][Full Text] [Related]
3. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
4. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
5. Health-related consequences of overactive bladder.
Wagner TH; Hu TW; Bentkover J; LeBlanc K; Stewart W; Corey R; Zhou Z; Hunt T
Am J Manag Care; 2002 Dec; 8(19 Suppl):S598-607. PubMed ID: 12516954
[TBL] [Abstract][Full Text] [Related]
6. Health and functional status, health events, use of healthcare services and costs associated with overactive bladder among the medically complex vulnerable elderly in the US.
Chuang CC; Yang E; Zou KH; Araiza A; Wang A; Luo X
Int J Clin Pract; 2019 Aug; 73(8):e13207. PubMed ID: 30011108
[TBL] [Abstract][Full Text] [Related]
7. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
8. The Relationship Between Anticholinergic Exposure and Falls, Fractures, and Mortality in Patients with Overactive Bladder.
Suehs BT; Caplan EO; Hayden J; Ng DB; Gaddy RR
Drugs Aging; 2019 Oct; 36(10):957-967. PubMed ID: 31359329
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States.
Durden E; Walker D; Gray S; Fowler R; Juneau P; Gooch K
Neurourol Urodyn; 2018 Jun; 37(5):1641-1649. PubMed ID: 29464813
[TBL] [Abstract][Full Text] [Related]
10. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
11. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
12. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
13. Increased Healthcare Resource Utilization and Direct and Indirect Costs in Patients with Depression and Comorbid Overactive Bladder: Evidence From a Retrospective, Matched Case-Control Cohort Analysis.
Shiozawa A; Hopson S; Fuldeore R; Stoelzel M; Ng D; Hairston J
Adv Ther; 2020 Nov; 37(11):4599-4613. PubMed ID: 32910419
[TBL] [Abstract][Full Text] [Related]
14. Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
Chen JV; Gahn JC; Nesheim J; Mudd PN
Pharmacoeconomics; 2022 Oct; 40(10):979-988. PubMed ID: 35881325
[TBL] [Abstract][Full Text] [Related]
15. The economic costs of overactive bladder in Germany.
Klotz T; Brüggenjürgen B; Burkart M; Resch A
Eur Urol; 2007 Jun; 51(6):1654-62; discussion 1662-3. PubMed ID: 17161521
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
Jumadilova Z; Varadharajan S; Girase P; Ollendorf DA
Am J Health Syst Pharm; 2006 Dec; 63(23):2357-64. PubMed ID: 17106009
[TBL] [Abstract][Full Text] [Related]
17. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of urgency urinary incontinence in the United States: a systematic review.
Coyne KS; Wein A; Nicholson S; Kvasz M; Chen CI; Milsom I
J Manag Care Pharm; 2014 Feb; 20(2):130-40. PubMed ID: 24456314
[TBL] [Abstract][Full Text] [Related]
19. Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.
Kinlaw AC; Jonsson Funk M; Conover MM; Pate V; Markland AD; Wu JM
Med Care; 2018 Feb; 56(2):162-170. PubMed ID: 29287033
[TBL] [Abstract][Full Text] [Related]
20. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Kachru N; Holmes HM; Johnson ML; Chen H; Aparasu RR
Curr Med Res Opin; 2021 Aug; 37(8):1303-1313. PubMed ID: 33890538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
